Avance Clinical Honored with Frost & Sullivan's 2025 Global Customer Value Leadership Award for Transformative Biotech CRO Services
SAN ANTONIO, May 14, 2025 /CNW/ -- Frost & Sullivan has named Avance Clinical the recipient of its 2025 Global Customer Value Leadership Award in the biotech contract research organization (CRO) sector, highlighting the company's outstanding performance in delivering exceptional client value through innovation, service excellence, and technology-enabled trial optimization. The accolade reinforces Avance Clinical's position as a trusted CRO partner that is uniquely equipped to support biotech sponsors navigating the complexities of early-phase research.
Each year, Frost & Sullivan undertakes a comprehensive, independent analysis to benchmark companies on two core criteria—strategy alignment and execution effectiveness. Avance Clinical demonstrated clear leadership across both dimensions, offering a compelling combination of agility, scientific rigor, and digital innovation that continues to shape the biotech CRO landscape.
According to Unmesh Lal, Vice President - Healthcare & Life Sciences at Frost & Sullivan, "Avance Clinical is positioning itself as a next-generation CRO with a deeply patient-centric and globally adaptive model. Under Yvonne Lungershausen's leadership, the company is striking a rare balance between innovation and regulatory rigor—leveraging technology to accelerate clinical trials while preserving scientific integrity. Their strategic focus on partnerships to drive global expansion, coupled with strong client retention and a commitment to quality, makes Avance a compelling player in the evolving biotech services landscape.
Avance Clinical's growth strategy is built on its ability to anticipate and respond to market shifts, whether through digital transformation, data-driven decision-making, or strategic geographic expansion. The company's integration of artificial intelligence into core clinical operations—such as protocol development, medical writing, and workforce optimization—enables faster, more reliable outcomes for biotech innovators.
By embedding intelligent automation into traditional manual workflows, Avance Clinical helps clients streamline study timelines while upholding the highest regulatory compliance and scientific integrity standards. These capabilities have positioned the company as a go-to CRO for sponsors seeking speed, quality, and flexibility in their clinical programs.
Avance Clinical Chief Executive Officer, Yvonne Lungershausen said, "We are honored to receive this recognition from Frost & Sullivan, whose deep industry expertise and thoughtful analysis have been invaluable in highlighting what truly matters to our customers. At Avance Clinical, we are driven to be a smarter, faster, and more strategic partner for our clients because every patient deserves a future — that mission is at the heart of everything we do."
Beyond its technical strengths, Avance Clinical distinguishes itself through a deeply customer-focused model. Through real-time milestone reviews, proactive risk mitigation, and transparent communication, the company fosters long-term client relationships built on trust, performance, and shared goals. Its structured project oversight, workforce training, and quality framework consistently drive high satisfaction and retention rates among biotech sponsors worldwide.
Frost & Sullivan recognizes Avance Clinical's ability to translate strategic foresight into measurable impacts, supporting biotech sponsors as they navigate increasing regulatory scrutiny, financial pressures, and extended development timelines. The company's dedication to continuous improvement, global expansion, and collaborative innovation ensures its clients remain competitive in a fast-changing market.
The Global Customer Value Leadership Award is one of Frost & Sullivan's highest honors, presented to organizations that elevate industry standards through breakthrough strategies and customer-centric delivery. Winners are selected based on demonstrated excellence in driving customer success, strengthening market standing, and translating strategic vision into scalable, high-impact outcomes.
Frost & Sullivan's Best Practices Awards are the result of extensive independent research, comparing market participants on performance indicators such as growth strategy, innovation, customer engagement, and operational execution. The awards celebrate companies that have risen above the competition to deliver best-in-class results and set benchmarks for success across global industries.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Contact:
Tarini Singh
E:
About Avance Clinical
Avance Clinical is a leading Contract Research Organization (CRO) offering biotech companies faster, more flexible, and higher-quality clinical trial services. As the largest premium full-service CRO headquartered in Australia, Avance Clinical delivers globally accepted data across Australia, New Zealand, Asia, North America, and Europe for international biotechs. With 30 years of experience and expertise spanning over more than 250 indications, the company provides comprehensive clinical research services from early to late-phase trials.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
28 minutes ago
- Cision Canada
FuelPositive issues clarification regarding a statement made in its August 13, 2025 Press Release
WINNIPEG, MB, Aug. 15, 2025 /CNW/ - FuelPositive Corporation (the "Company") (TSXV: NHHH) (OTCQB: NHHHF) wishes to clarify a statement made in its August 13, 2025 Press Release. The Company reported: "…The first FP300 system has been delivered, completed its final certification, and is ready for activation. This milestone will trigger the demonstration phase and accelerate the ramp-up to manufacturing the larger FP1500 system, built to serve farms of approximately 10,000 acres…" The correct wording of this section of the Press Release should have read: "…The first FP300 system has been delivered and is prepared for the completion of its final certification and activation. This milestone will trigger the demonstration phase and accelerate the ramp-up to manufacturing the larger FP1500 system, built to serve farms of approximately 10,000 acres…" The Company apologizes for any confusion this may have caused. About FuelPositive: Building the Future of Farming Now FuelPositive is a Canadian clean-tech company transforming agriculture through decentralized, on-farm Green Ammonia production systems. By enabling farmers to generate their own green nitrogen fertilizer and carbon-free fuel on site, the Company is redefining the ammonia industry and putting control directly into the hands of those who feed the world. This model reduces reliance on volatile supply chains and unpredictable pricing, helping farmers secure their livelihoods and plan for the future. Each tonne of ammonia produced by a FuelPositive system prevents up to two tonnes of CO₂e emissions, offering both environmental and economic advantages. Designed for simplicity, dependability, and remote monitoring, the Company's containerized systems effortlessly integrate into farm operations. Made in Canada for Canadian conditions, they are engineered to be as straightforward to operate as they are impactful. The first FP300 demonstration system, installed on an 11,000-acre grain farm in Sperling, Manitoba, is designed to produce 100 metric tonnes of Green Ammonia each year. This unit serves as the foundation for the FP1500 commercial system, which can generate 500 metric tonnes annually for farms of approximately 10,000 acres. The systems are powered by sustainable electricity and produce carbon-free ammonia on demand, providing a decentralized, cost-effective alternative to fossil-fuel-based fertilizers and fuels. The delivery of the FP300 to Tracy and Curtis Hiebert's farm in Sperling, Manitoba, marked a milestone in sustainable agriculture. Once activated, the system will demonstrate how local production can strengthen farm economics, reduce environmental impact, and build resilience against climate change, market instability, and global supply disruptions. FuelPositive aims to position Canada as a global centre of excellence for decentralized Green Ammonia production and to establish a world-leading manufacturing hub. Supported by Stantec, one of the world's top engineering and consulting firms, this initiative will drive economic growth, create high-value jobs in engineering, science, and skilled trades, and promote a more resilient and sustainable food system. FuelPositive is located in Ontario and Manitoba (Canada) and trades on the TSX Venture Exchange under the symbol NHHH, as well as on the OTCQB in the USA under the symbol NHHHF. Cautionary Statement Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains certain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") that are based on expectations, estimates and projections as of the date of this news release. The information in this release about future plans and objectives of the Company are forward-looking statements. These forward-looking statements are based on assumptions and estimates of management of the Company at the time they were made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking information is provided to provide information about management's expectations and plans relating to the future. The Company disclaims any intention or obligation to update or revise any forward-looking information or to explain any material difference between subsequent actual events and such forward-looking information, except to the extent required by applicable law. SOURCE FuelPositive Corp.
Cision Canada
an hour ago
- Cision Canada
True North Commercial REIT Announces August 2025 Distribution
/NOT FOR DISTRIBUTION IN THE U.S. OR OVER U.S. NEWSWIRES/ TORONTO, Aug. 15, 2025 /CNW/ - True North Commercial Real Estate Investment Trust (TSX: (the " REIT") today announced its August 2025 monthly cash distribution in the amount of $0.0575 per trust unit (" Unit"), payable on September 15, 2025 to holders of Units of record at August 31, 2025. About the REIT The REIT is an unincorporated, open-ended real estate investment trust established under the laws of the Province of Ontario. The REIT currently owns and operates a portfolio of 38 properties consisting of approximately 4.5 million square feet in urban and select strategic secondary markets across Canada. The REIT is focused on growing its portfolio principally through acquisitions across Canada and such other jurisdictions where opportunities exist. For more information regarding the REIT, please visit or the REIT's website at
Cision Canada
an hour ago
- Cision Canada
Killam Apartment REIT Announces August 2025 Distribution
HALIFAX, NS, Aug. 15, 2025 /CNW/ - Killam Apartment REIT (TSX: is pleased to announce its August 2025 monthly distribution. The distribution of $0.06 per unit will be paid on September 15, 2025, to unitholders of record on August 29, 2025. Killam Apartment REIT offers a distribution reinvestment plan (the "DRIP"). Eligible unitholders may reinvest their cash distributions, on each distribution payment date, in additional units. Participating unitholders will receive an additional distribution of units representing 3% of the amount of the distribution reinvested pursuant to the DRIP. About Killam Apartment REIT Killam Apartment REIT, based in Halifax, Nova Scotia, is one of Canada's largest residential real estate investment trusts, owning, operating, managing and developing a $5.5 billion portfolio of apartments and manufactured home communities. Killam's strategy to enhance value and profitability focuses on three priorities: 1) increasing earnings from existing operations, 2) expanding the portfolio and diversifying geographically through accretive acquisitions which target newer properties and through the disposition of non-core assets, and 3) developing high-quality properties in its core markets. For information, please contact: Claire Hawksworth, CPA Senior Manager, Investor Relations [email protected] (902) 442-5322 Note: The Toronto Stock Exchange has neither approved nor disapproved of the information contained herein.
